Targeting PSMA in Advanced Prostate Cancer

Experts in genitourinary oncology specializing in advanced prostate cancer discuss the evolution of personalized approaches for patients with metastatic castration-resistant prostate cancer (mCRPC).

Oliver Sartor, MD, reviews the treatment approaches that are currently available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Ulka N. Vaishampayan, MD, discusses somatic and germline genetic testing for patients with advanced prostate cancer.

Practical considerations for the timing of genomic testing throughout lines of therapy for patients with advanced prostate cancer.

Oliver Sartor, MD, discusses the use of phenotypic biomarkers such as prostate-specific membrane antigen (PSMA), and how these biomarkers can be utilized for prediction of prognosis as well as responsiveness to therapy.

Oliver Sartor, MD, and Ulka Vaishampayan, MD, discuss noninvasive imaging with PSMA PET/CT for patients with advanced prostate cancer.

Key opinion leaders expand on the broad clinical utility of prostate-specific membrane antigen (PSMA) for patients with advanced prostate cancer.

Oliver Sartor, MD, reviews clinical data from the TheraP trial looking at the activity of 177Lu-PSMA617 in patients with metastatic castration-resistant prostate cancer.

A review of the PSMA-targeted radioligand therapies that are currently in development.

A look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).